Overview: NGS Neuromuscular Panel Sequencing TestIntroduction: The NGS Neuromuscular Panel Sequencing Test sequences neuromuscular genes to diagnose disorders, causing muscle weakness. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected neuromuscular disorders, such as muscular dystrophies or myopathies.
Other Names: Neuromuscular NGS Assay, Neuromuscular Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Neuromuscular sequencing began in the 1990s with myopathy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences neuromuscular genes to diagnose disorders, guides treatment, and evaluates patients with muscle weakness.
Test Parameters: 1. Neuromuscular Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle weakness, myalgia, or neuromuscular symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, myalgia, cramps, or family history of neuromuscular disorders. Include current medications, especially corticosteroids.
Consent: Written consent required, detailing the tests purpose, neuromuscular disorder implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze neuromuscular genes (e.g., DMD, GNE). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for neuromuscular disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm neuromuscular disorders, guiding supportive care or genetic counseling. Negative results may require muscle biopsy.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Muscle biopsy, EMG, or creatine kinase levels to confirm neuromuscular disorder diagnosis.
Test Limitations: Not all neuromuscular disorders are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Neuromuscular Guidelines, 2023; Neurology, Mercuri E, 2022.
